By helping regulate appetite and blood sugar levels, these innovative treatments can support your journey towards achieving a healthier lifestyle
ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes
Eternity Health Partners provides the support you need along with high-quality CJC 1295 to help you achieve your health goals
Moreover, they obtained a decrease in average HbA1c of up to 2.2 percentage points
For those with higher demands, the right supplements can meaningfully close the gap